DOCONEXENT
Other / unclassified targets PCSK9, PPARG via activation
Trials 38 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 8 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03634644 Comparator | Nov 2017 → Mar 2019 | spermatogenic failure | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03936621 Comparator | Jun 2019 → Jun 2021 | lung cancer | British Columbia Cancer Agency | Unknown | No outcome recorded |
| Phase 2 | NCT01661764 Comparator | Feb 2013 → Dec 2016 | adenomatous colon polyp | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT01471652 Comparator | Mar 2012 → Feb 2013 | myalgic encephalomeyelitis/chronic fatigue syndrome | Columbia University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00323414 Comparator | Apr 2006 → Dec 2011 | fatty liver disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01745263 Comparator | Dec 2012 → Nov 2017 | — | University of Zurich | Completed | No outcome recorded |
| Phase 3 | NCT00345176 Comparator | Sep 2006 → Oct 2012 | age-related macular degeneration, cataract | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02137408 Comparator | Dec 2014 → Nov 2015 | hypertension, pregnancy-induced | Children's Hospital Medical Center, Cincinnati | Withdrawn | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 53 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOCONEXENT | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | 22:6 n-3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | C22:6 (n-3) | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | Cervonic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | DHA | “The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA), Vitamin E and Choline in children or adolescents with...” NCT01934777 ↗26“This study aimed to compare the efficacy of docosahexaenoic acid (DHA) plus piracetam with piracetam alone in reducing the frequency and severity of BHS in infants and...” PMID 37651975 ↗ Aug 2023 “Overall, treatment data in MDD support a role for EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in combination or EPA as the omega-3 fatty acid intervention.” NCT00825994 ↗ “Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks” NCT00323414 ↗ “such as eicosapentanoic acid [EPA] and docosahexanoic acid [DHA] may reduce the risk of colorectal cancer.” NCT01661764 ↗ “5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily” NCT01814527 ↗ “treatment with docosahexaenoic acid (DHA) for 12 weeks at 1000 mg twice daily as compared to placebo” NCT01849250 ↗ “Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART” NCT02005900 ↗ “Docosahexaenoic acid (DHA) is an omega-3 fatty acid commonly found in both fish oils and algae.” NCT01903525 ↗ “Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA” NCT00976872 ↗ “Participants will be randomized to 200 mg of docosahexaenoic acid (DHA) administered PO daily” NCT02137408 ↗ “Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day” NCT05796401 ↗ “Moderate intake of docosahexaenoic acid (DHA) may favor the lowering of oxidative stress.” PMID 27914512 ↗ Oct 2016 “Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) are the most common n-3 PUFA.” NCT03634644 ↗ “Intake of dietary docosahexaenoic acid (DHA) among toddlers is low.” PMID 30357263 ↗ Dec 2018 “Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day” NCT04151758 ↗ “Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).” NCT00290056 ↗ “Docosahexaenoic Acid (DHA) Dietary Supplement” NCT00060749 ↗ “docosahexaenoic acid (DHA) enriched oil” NCT00004827 ↗ “Docosahexaenoic acid (DHA)” NCT00014027 ↗ “Docosahexaenoic acid (DHA)” NCT03831178 ↗ “docosahexaenoic acid (DHA)” NCT00885313 ↗ |
| Known as | Doconexento | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | Docosaheaenoic-acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | Docosahexaenoate | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | docosahexaenoic acid | “Daily supplementation with long-chain ω-3 polyunsaturated fatty acids (350-mg docosahexaenoic acid [DHA] + 650-mg eicosapentaenoic acid [EPA]), macular xanthophylls (10-mg...” PMID 24638908 ↗ May 201440“The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA) and Vitamin D in children and adolescents with biopsy-proven...” NCT02098317 ↗ “Overall, treatment data in MDD support a role for EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in combination or EPA as the omega-3 fatty acid intervention.” NCT00825994 ↗ “Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks” NCT00323414 ↗ “Docosahexaenoic Acid Plus Piracetam Versus Piracetam Alone for Treatment of Breath-Holding Spells in Children: A Randomized Clinical Trial.” PMID 37651975 ↗ Aug 2023 “Lower blood levels of the omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) are correlated with worse cognitive functions” PMID 37874103 ↗ 2023 “Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.” NCT03101540 ↗ “5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily” NCT01814527 ↗ “Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children.” PMID 23220074 ↗ Dec 2012 “Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months” NCT02103842 ↗ “Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day” NCT05796401 ↗ “two fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on metabolism.” NCT02514070 ↗ “Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) are the most common n-3 PUFA.” NCT03634644 ↗ “2.4 g eicosapentaenoic acid (EPA) + 1.2 g docosahexaenoic acid (DHA)/day” PMID 36532545 ↗ Dec 2022 “Eicosapentaenoic acid AND Docosahexaenoic acid” NCT01745263 ↗ “4. Docosahexaenoic acid: oral gel capsule bid” NCT01471652 ↗ “DHA (Docosahexaenoic Acid)” NCT00440050 ↗ “Docosahexaenoic acid (DHA)” NCT03831178 ↗ “docosahexaenoic acid (DHA)” NCT03101527 ↗ “Docosahexaenoic acid” NCT03965988 ↗ |
| Known as | Docosahexaenoic acid (c22:6 n3) | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | docosahexaenoic acid (DHA) | “docosahexaenoic acid (DHA)” NCT03101527 ↗1“docosahexaenoic acid (DHA)” NCT03101540 ↗ |
| Known as | docosahexanoic acid | “The purpose of this research study is to measure the safety (side effects) of an Omega 3 Fatty acid called docosahexanoic acid (DHA) and measure the dyskinesia (involuntary...” NCT01563913 ↗4“Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA” NCT00976872 ↗ |
| Known as | SC411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02604368 ↗ |
| Action | Inhibit | “reduces normal breast tissue levels of tumor necrosis factor-alpha (TNF-alpha)” NCT01849250 ↗ |
| Modality | Other / unclassified | “algae (ocean plant) omega-3 fat supplement (DHA)” NCT00360217 ↗ |
| Route | Oral | “Oral DHA supplementation continues daily for 3 years.” NCT00004827 ↗ |
| Target | PPARG | “At a molecular level, DHA acts as a stimulator of the nuclear receptor PPAR-gamma” NCT02005900 ↗ |